cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Athira Pharma Inc
16 own
10 watching
Current Price
$3.8
$-0.42
(-9.95%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
143.71M
52-Week High
52-Week High
14.22
52-Week Low
52-Week Low
2.53
Average Volume
Average Volume
0.69M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization143.71M
icon52-Week High14.22
icon52-Week Low2.53
iconAverage Volume0.69M
iconDividend Yield--
iconP/E Ratio--
What does the Athira Pharma Inc do?
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company s lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Read More
How much money does Athira Pharma Inc make?
News & Events about Athira Pharma Inc.
Globe Newswire
29days ago
Advancing small molecule therapeutic candidates with clinical and preclinical data suggesting potential neuroprotective, neurotrophic, procognitive and disease-modifying effects Fosgonimeton Phase 2/3 LIFT-AD study in mild-to-moderate Alzheimers disease is progressing with targeted enrollment ...
Globe Newswire
1month ago
Data demonstrate fosgonimeton enhances the HGF/MET system, promoting neuroprotective, neurotrophic and procognitive effects in multiple cell and animal modelsBOTHELL, Wash., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused ...
Ticker Report
1month ago
Shares of Athira Pharma, Inc. (NASDAQ:ATHA Get Rating) have been given a consensus recommendation of Moderate Buy by the six analysts that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have assigned...
Globe Newswire
1month ago
PHILADELPHIA, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Athira Pharma, Inc. (Athira or the Company) (NASDAQ: ATHA) on behalf of the Companys long-term investors. The investigation seeks to determine whether the members of Athiras board of directors violated...
Globe Newswire
2 months ago
Fosgonimeton treatment-related reductions in biomarkers of neurodegeneration (NfL) and neuroinflammation (GFAP) significantly correlated with improvements in clinical outcomes as assessed by the GST, a composite score of cognition (ADAS-Cog11) and function (ADCS-ADL23) Data demonstrate fosgonimeton ...
Frequently Asked Questions
Frequently Asked Questions
What is Athira Pharma Inc share price today?
plus_minus_icon
Can Indians buy Athira Pharma Inc shares?
plus_minus_icon
How can I buy Athira Pharma Inc shares from India?
plus_minus_icon
Can Fractional shares of Athira Pharma Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Athira Pharma Inc stocks?
plus_minus_icon
What is today’s traded volume of Athira Pharma Inc?
plus_minus_icon
What is today’s market capitalisation of Athira Pharma Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Athira Pharma Inc?
plus_minus_icon
What percentage is Athira Pharma Inc down from its 52-Week High?
plus_minus_icon
What percentage is Athira Pharma Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$3.8
$-0.42
(-9.95%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00